NCT01739530

Safety of Repaircell in Healthy Volunteers

Phase I Study to Evaluate Safety of Repaircell in Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 5 (actual)
• Sponsor: Anterogen Co., Ltd. · Industry
• Sex: Male
• Age: 19 Years
• Healthy volunteers: Accepted

Summary

Allogenic differentiated adipocytes (ANT-adip-AL) is produced by well-established techniques including cell harvesting from lipoaspirates obtained from healthy donors, expansion of adipose tissue derived stem cells, and differentiation into pure and immature adipocytes. This was an open-label study. Subjects were received subcutaneous injection of ANT-adip-AL and followed for 8 weeks according to the clinical trial protocol.

Conditions

• Healthy

Interventions

Type	Name	Description
BIOLOGICAL	Repaircell	allogenic differentiated adipocyte

Timeline

• Start date: 2009-03-01
• Primary completion: 2009-11-01
• Completion: 2009-12-01
• First posted: 2012-12-03
• Last updated: 2012-12-04

Locations

1 site across 1 country: South Korea